LAG3 and neoplasm: However, phase III trials, including SKYSCRAPER-01 and SKYSCRAPER-02, have revealed challenges, with no significant survival benefits observed in NSCLC and small cell lung cancer, suggesting limitations due to tumor heterogeneity, compensatory immune checkpoints (e.g., TIM-3, LAG-3), and inadequate patient selection criteria.